Combined Immunostimulation and Conditional Cytotoxic Gene Therapy Provide Long-term Survival in a Large Glioma Model

Sumia Ali,1 Gwendalyn D. King,2 James F. Curtin,2 Marianela Candolfi,2 Weidong Xiong,2 Chunyan Liu,3 Mariana Puntel,4 Queng Cheng,3 Jesus Prieto,5 Antoni Ribas,3 Jerzy Kupiec-Weglinski,3 Nico van Rooijen,6 Hans Lassmann,7 Pedro R. Lowenstein,1,2 and Maria G. Castro1,2

1Molecular Medicine and Gene Therapy Unit, University of Manchester, Manchester, United Kingdom; 2Gene Therapeutics Research Institute, Cedars-Sinai Medical Center, and Departments of Medicine and Molecular and Medical Pharmacology, Medicine Hematology and Oncology, and Surgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California; 3Department of Medicine, School of Medicine, University of Navarra, Pamplona, Spain; 4VUmc FdG, Amsterdam, the Netherlands; and 5Institute of Brain Research, Department of Neuroimmunology, University of Vienna, Vienna, Austria

Abstract

In spite of preclinical efficacy and recent randomized, controlled studies with adenoviral vectors expressing herpes simplex virus-1 thymidine kinase (HSV1-TK) showing statistically significant increases in survival, most clinical trials using single therapies have failed to provide major therapeutic breakthroughs. Because glioma is a disease with dismal prognosis and rapid progression, it is an attractive target for gene therapy. Preclinical models using microscropic brain tumor models (e.g., ≤0.3 mm3) may not reflect the pathophysiology and progression of large human tumors. To overcome some of these limitations, we developed a syngeneic large brain tumor model. In this model, administration of single therapeutic modalities, either conditional cytotoxicity or immunostimulation, fail. However, when various immunostimulatory therapies were delivered in combination with conditional cytotoxicity (HSV1-TK), the only combined delivery of fms-like tyrosine kinase ligand (Flt3L) and HSV1-TK significantly prolonged the survival of large tumor-bearing animals (≥80%; P ≤ 0.005). When either macropathies or CD4+ cells were depleted before administration of viral therapy, TK + Flt3L therapy failed to prolong survival. Meanwhile, depletion of CD8+ cells or natural killer cells did not affect TK + Flt3L efficacy. Spinal cord of animals surviving 6 months after TK + Flt3L were evaluated for the presence of autoimmune lesions. Whereas macropathies were present within the corticospinal tract and low levels of T-cell infiltration were detected, these effects are not indicative of an overt autoimmune disorder. We propose that combined Flt3L and HSV1-TK adenoviral-mediated gene therapy may provide an effective large glioma treatment with increased efficacy in clinical trials of glioma.

(Cancer Res 2005; 65(16): 7194-204)

Introduction

Glioblastoma is the most common type of brain tumor in adults and accounts for 25% of all brain tumors diagnosed (1, 2). Unfortunately, glioblastoma is also an extremely malignant tumor with a mean survival of ~12 months postdiagnosis. Aggressive surgical resection can be combined with either chemotherapy or radiotherapy to reduce tumor burden (3); however, glioblastoma invariably recurs within 6 to 12 months. Consequently, novel therapies are urgently needed to improve the prognosis of glioblastoma patients (3).

Using a syngeneic (CNS-1 cells) intracranial glioma model in Lewis rats, we have shown that in spite of powerful antitumor effects, RAdTK, which carries the herpes simplex virus-1 thymidine kinase (HSV1-TK) transgene combined with systemic ganciclovir, also elicits severe adverse effects in long-term survivors (4). Using syngeneic CNS-1 cells in Lewis rats, we previously evaluated adenoviral gene therapies in microscopic glioma models. Intratumoral injection of RAdTK or RAdFlt3L (an adenovirus expressing the human soluble Flt3L) were effective in causing tumor regression when used as single therapies in the microscopic brain tumor model (4, 5). Other experimental gene therapies include the expression of tumor suppressors, oncogene antagonists, angiogenesis inhibitors, immunostimulatory approaches, and more recently the use of replication-competent viral vectors and stem cells (6–9). These approaches have only been tested in microscopic brain tumor models (tumor size ≤0.3 mm3) at time of treatment) in preclinical studies; in the clinical setting, most experimental approaches have generally only provided marginally significant results (7, 9–11). In preclinical studies, therapies are usually administered when the tumor mass is very small and are efficient at inhibiting tumor progression. However, microscopic tumor models may not mimic the human disease state where well-established, infiltrating tumor masses are encountered. Therefore, the experimental availability of a syngeneic large glioma tumor model in an immunocompetent animal is critical to assess the efficacy of adenoviral gene therapy approaches.

In the large model, RAdFlt3L, RAdCD40L, and RAdIL-12 were ineffective when used as single therapies. In contrast, coadministration of RAdFlt3L with RAdTK in this large model rescued 80% of animals. All other single or combined treatments tested did not significantly improve long-term survival of rats harboring large intracranial tumors. Immunosuppression using cyclosporine A reduced survival to levels attained by the treatment of RAdTK alone, suggesting a role for the immune system in the tumor regression process. Depletion of either macropathies or CD4+ cells before adenoviral treatment likewise reduced survival, whereas depletion of CD8+ or natural killer (NK) cells did not affect treatment efficacy. In summary, combined immunostimulatory and conditional cytotoxic gene therapy, using Flt3L in...
combination with TK, will provide a clinically relevant platform to further develop this experimental treatment for clinical trials for glioblastoma.

Materials and Methods

Adenoviral Vectors

RAdFlt3-L, expressing the human soluble Fms-like tyrosine kinase ligand; RAd35, expressing β-galactosidase; RAd128, expressing HSV1-TK; RAdCD40L, and RAdIL12: production and characterization. RAdS used in this study are first-generation, replication-defective recombinant adenovirus type 5 vectors expressing the transgenes under the transcriptional control of the human cytomegalovirus intermediate early promoter within the E1 region. RAd35, an adenovirus encoding LacZ under the control of the hCMV promoter, was described by Wilkinson and Akrigg (12) and has been used previously by us (13); herein, it is called RAd β-gal. RAd128 has also been previously described and is indicated as RAd TK throughout (14). RAd0 carries no transgene and was used in our studies to balance total viral load between experimental conditions. RAdS expressing CD40L and IL-12 have been described in detail elsewhere (15–17).

Cell culture and infection

CNS-1 cells infection for Flt3L expression. CNS-1 cells (1 × 10^6) were mock infected or virally infected with RAdFlt3L, RAdTK, or RAdFlt3L + RAdTK at a multiplicity of infection (MOI) of 250 for 48 hours. Total viral load in single infections was balanced with RAd0. Supernatants were cleared of cellular debris and stored at −20°C until use in human Flt3L ELISA or β-galactosidase enzymatic activity assay. Cell lysates were harvested by subjecting cells to three freeze-thaw cycles. Lysates were stored at −20°C until used in immunohistological, Flt3L ELISA, and β-galactosidase enzyme activity assays.

ELISA for hsFlt3L. ELISA for human Flt3L (R&D Systems, Minneapolis, MN) was conducted exactly as described by the manufacturer using cell lysates and supernatants collected from CNS-1 cells infected (MOI 250, 48 hours) above.

β-galactosidase enzymatic activity assay. β-galactosidase activity was measured by conversion of o-nitrophenyl-β-D-galactopyranoside in 10 mmol/L MgCl2/0.45 mol/L 2-mercaptoethanol at 37°C. The enzymatic reaction was stopped with 1 mol/L Na2CO3. Standard curves were generated using bovine serum albumin (protein standard) or o-nitrophenol (nitrophenol standard). β-galactosidase enzymatic activity was calculated using the following formula: enzymatic activity/μmol [o-nitrophenol] / (time × [protein]).

Western blots.

Thirty micrograms of cell lysate were electrophoretically separated on a 12% SDS-PAGE before transfer to polyvinylidene difluoride membranes (Amersham Biosciences, Piscataway, NJ). Membranes were blocked using 5% nonfat dry milk in PBST (0.1% Tween 20). Primary antibodies, generated in our laboratory, to β-galactosidase (1:2,000), TK (1:1,000), and hsFlt3L (1:1,000) were incubated overnight at 4°C. The anti-hsFlt3L antibody was generated by injection of an antigenic peptide (CETVHHRVSQGLDL) into New Zealand white rabbits (New England Peptides, Gardner, MA). The antigenic peptide was coupled to keyhole limpet hemocyanin via the cysteine residue. Rabbits were bleed and immunized 14 and 28 days later with antibodies collected on days 35 and 42. Antibody specificity was verified by ELISA to the antigenic peptide and Western blotting to the purified Flt3L protein (results not shown). All primary antibodies were detected with goat anti-rabbit hors eradish peroxidase secondary antibody (DAKO, Glostrup, Denmark). Secondary antibody visualization was detected with ECL (Amersham Biosciences).

Intracranial Glioma Models

Development of large brain tumor model. Animals treated on day 3 after CNS-1 cell implantation are referred to as having a small tumor, whereas animals treated on day 10 after CNS-1 cell implantation are referred to as having a large tumor (see Fig. 2 for reference sizes). To develop a large glioma tumor model, male Lewis rats (220–250 g) were unilaterally injected into the striatum (+1 mm bregma, +3 mm lateral, and −4 mm from the dura) with 5 × 10^7 CNS-1 cells. Animals were sacrificed at 3, 6, and 10 days post tumor implantation (n = 10). Forty-millimeter-thick serial brain sections were cut using a vibratome. The section in which the tumor filled the largest area of the striatum was used for the calculation of tumor size. To determine the size of the tumors at each point, the following equation, which determines the volume of an ovoid, was used: 4/3 π(ab2), where a is the shortest radius of cross-sectional face of the tumor, b is the largest radius of the cross-sectional face of the tumor, and c is the total thickness of the tumor in millimeter.

To test survival of single therapies, doses of 8 × 10^6 infectious units (i.u.) of either RAdTK or RAdFlt3L were injected intratumorally 3, 6, and 10 days post CNS-1 cell implantation to determine the time point post tumor implantation at which single therapies would fail (i.e., animals succumb within 30 days). On the day after the injection of the virus, 25 mg/kg ganciclovir (Cytovene, Roche Products, Welwyn Garden City, United Kingdom) was injected ip twice daily for 7 days into all experimental animals. Control animals received saline or RAd β-gal. Animals were monitored daily and terminally perfused-fixed at the first signs of moribund behavior. Brains were removed for histologic examination.

Gene therapy in the treatment of the large glioma tumor model. Groups of male Lewis rats (n = 10) were implanted with CNS-1 cells as above, and 10 days later viral vectors were injected intratumorally with a total viral load of 2 × 10^7 i.u. In injections of individual virus, 1 × 10^7 i.u. was balanced with an additional 1 × 10^7 i.u. RAd0, an adenoviral vector expressing no transgene. Beginning 24 hours after injection of the RAdS, 25 mg/kg ganciclovir (Cytovene, Roche Products) was injected ip twice daily for 7 days. All animals including controls received ganciclovir. Animals were monitored daily and terminally perfused-fixed at the first signs of moribund behavior.

Immune cell depletion in a large glioma model. Hybridoma cell lines for CD8+ cell depletion [OX-8, European Collection of Animal Cell Cultures (ECACC), Porton Village, United Kingdom] and CD4+ cell depletion (OX-34, ECACC), NK cell depletion (NK 3.2.3, provided by William Chambers, University of Pittsburgh Medical Center, Pittsburgh, PA) were produced by Bioexpress Cell Culture Services (West Lebanon, NH). Depletion of macrophages was conducted with liposome encapsulated clodronate (Cl2MDP; ref. 23). Clodronate was a gift of Roche Diagnostics GmbH (Mannheim, Germany). It was then encapsulated in liposomes as previously described (23). One milliliter of suspensions of liposomes containing 6 mg clodronate was injected per 100 mg animal weight. Groups of Lewis rats (n = 6) were unilaterally injected with 5,000 CNS-1 cells into striatum. Nine days later, 1 mg of OX-8, OX-34, or normal mouse IgG; 0.5 mg of NK 3.2.3, or 2 mL of clodronate or PBS-filled liposomes were injected ip into tumor-bearing Lewis rats. Animals surviving 2 weeks after initial immune cell depletion were injected ip one additional time. On day 10 after CNS-1 implantation, animals received intratumoral injection of either saline or RAdTK + RAdFlt3L. GCV was administered twice daily for 7 days. Animals were sacrificed by terminal perfusion at the first signs of moribund behavior. To ensure that depleting antibodies were thoroughly and accurately depleting...
their respective immune cell types, naïve animals were injected as above \((n = 4)\). Spleens were collected 7 days later and analyzed by flow cytometry.

Splenocytes were harvested and RBC lysed with ACK. Cells were counted and labeled with antibodies for analysis by flow cytometry. Cells \((1 \times 10^6)\) were resuspended in 1 mL of cell surface staining buffer \((0.1 \text{ mol/L PBS, without Ca}^{2+}, \text{Mg}^{2+}, \text{with } 1\% \text{ fetal bovine serum, } 0.1\% \text{ sodium azide})\). Cells were washed and resuspended in 100 \(\mu\text{L}\) cell surface staining buffer containing the combinations of antibodies described below before incubation in the dark for 30 minutes at 4°C. Samples were washed in cell surface staining buffer and analyzed by flow cytometry. CD4 and CD8 cells were detected by labeling with CD3-FITC, CD4-PE-Cy5, CD8-PE. NK cells were detected by labeling with CD3-FITC and CD161a-PE. Macrophages were detected by labeling with CD45-PE, CD4-PE-cy5, CD11b-FITC (all antibodies from BD Pharmingen, San Jose, CA).

**Cyclosporine A treatment.** In immunosuppression experiments, animals were immunosuppressed beginning 7 days after CNS-1 cell implantation. Animals received 10 \(\text{mg/kg}\) of cyclosporine A \((\text{Neoral, Sandoz})/300 \text{ \(\mu\text{L}\)} \text{ olive oil given p.o. by gavage twice daily until the termination of the experiment. Control animals were given 300 \(\mu\text{L}\) olive oil. Whole blood cyclosporine A concentrations were measured using a monoclonal RIA kit, following the instructions provided by the manufacturer (Incstar, Stillwater, MN).

All animal studies were conducted in accordance with the institutional guidelines and oversight of the Department of Comparative Medicine, Cedars-Sinai Medical Center, Los Angeles, CA.

**Brain Immunohistochemistry**

Forty-micrometer-thick coronal sections were cut through the striatum using a vibratome. Free-floating immunohistochemistry was done to detect inflammatory and immune cell markers. Endogenous peroxidase was inactivated with 0.3% hydrogen peroxide, and sections were blocked with 10% horse serum (Life Technologies, Carlsbad, CA) before incubating overnight with primary antibody. Antibodies ED1 \((1:1,000)\), CD8 \((1:1,000)\), CD45R \((1:100)\), CD161a \((1:500)\), MHC I \((1:1,000)\), and MHC II \((1:1,000)\) were used to label CNS-1 cells. Secondary antibodies were biotinylated goat anti-rat, goat anti-mouse, goat anti-rabbit, or goat antinegine (RAdTK as our positive therapeutic control treatment). We sought to determine whether tumor volume significantly affects survival when treated with recombinant adenoviral vectors using RAdTK as our positive therapeutic control treatment. Animals were treated with RAdTK, RAd\(\beta\)gal, or saline 3, 6, and 10 days later (i.e., at times of progressively larger tumor mass). The tumor volume was found to increase 140-fold between days 3 and 10, growing from 0.25 to 35 \(\text{mm}^3\) (Fig. 2A1-A3). We sought to determine whether tumor volume significantly affects survival when treated with recombinant adenoviral vectors using RAdTK as our positive therapeutic control treatment. Animals were treated with RAdTK, RAd\(\beta\)gal, or saline 3, 6, and 10 postimplantation of CNS-1 cells. In agreement with previous studies undertaken by our group and others \((4, 5, 24-28)\), RAdTK treatment was 100% effective when delivered 3 days post tumor implantation, 80% effective when injected 6 days post tumor implantation, and only 20% effective when given 10 days post tumor implantation (Fig. 2B). Our results highlight the importance of tumor size on the efficacy of various adenoviral-mediated glioma therapies. Furthermore, this model reproduces more closely the human disease condition where tumor size at the time of treatment determines the treatment outcome.

**Development of a Large Syngeneic Glioma Model where Single Gene Therapies Fail**

In previous work, we had implemented successful gene therapy strategies using a microscopically syngeneic CNS-1 glioma model \((4, 5)\). To develop a large model of glioma, we implanted \(5,000\) CNS-1 cells and injected RAds 3, 6, and 10 days later (i.e., at times of progressively larger tumor mass). The tumor volume was found to increase 140-fold between days 3 and 10, growing from 0.25 to 35 \(\text{mm}^3\) (Fig. 2A1-A3). We sought to determine whether tumor volume significantly affects survival when treated with recombinant adenoviral vectors using RAdTK as our positive therapeutic control treatment. Animals were treated with RAdTK, RAd\(\beta\)gal, or saline 3, 6, and 10 postimplantation of CNS-1 cells. In agreement with previous studies undertaken by our group and others \((4, 5, 24-28)\), RAdTK treatment was 100% effective when delivered 3 days post tumor implantation, 80% effective when injected 6 days post tumor implantation, and only 20% effective when given 10 days post tumor implantation (Fig. 2B). Our results highlight the importance of tumor size on the efficacy of various adenoviral-mediated glioma therapies. Furthermore, this model reproduces more closely the human disease condition where tumor size at the time of treatment determines the treatment outcome.
Combined Treatment with RAdFlt3L + RAdTK
Significantly Improves the Long-term Survival of Rats
with Large Brain Tumors

In view of the results shown in Fig. 2, we sought to develop a
combined gene therapy strategy aimed at promoting long-term
survival and tumor regression in animals bearing large intracranial
gliomas. Dendritic cells are absent from the naive brain, but are
detected within the brain under conditions of inflammation (29–32).
The lack of dendritic cells from the brain, together with the high
levels of immunosuppressive transforming growth factor-β
expressed by glioblastomas (33), could help explain the difficulties in stimulating antiglioma immune responses. We hypothesized that in the large model, codelivery of RAdTK with a powerful immune stimulant could provide the necessary signals to trigger an effective antitumor immune response. We tested codelivery with three potential candidates to stimulate immune responses (i.e., Flt3L, CD40L, and IL-12). Codelivery of the conditional cytotoxic gene therapy, TK with Flt3L, would increase the number of dendritic cells (34), whereas CD40L would activate dendritic cells (35). IL-12 would stimulate the immune responsiveness of various immune cell types (36, 37). We hypothesized that TK-mediated killing of tumor cells would provide antigenic tumor epitopes to Flt3L-stimulated dendritic cells in situ that could eventually stimulate an antitumor immune response. This in turn would result in tumor elimination and prolonged survival.

Our results show that the combined treatment with RAdTK + RAdFlt3L rescued a highly significant percentage of animals from tumor-induced death (Fig. 3A). Even as late as 6 months after tumor implantation, >70% of animals remained alive, compared with animals in all control groups (i.e., treated with saline, RAd0, RAdFlt3L, RAdIL-12, or RAdCD40L), which were all dead by day 25 post tumor implantation (Fig. 3A-C). RAdTK alone only protected 20% of animals, and this protection was not increased by the addition of RAdIL12 (Fig. 3C). Although treatment with RAdTK plus RAdCD40L rescued 40% of the animals, this value failed to reach statistical significance compared with animals treated with TK alone (Fig. 3B).

Immunosuppression blocks RAdTK + Flt3L–Mediated tumor regression. To determine if combined gene therapy with RAdTK + RAdFlt3L was acting through an immune-mediated mechanism, we repeated the survival experiment but a group of animals was treated with the powerful immunosuppressant, cyclosporine A, twice daily (38). We detected circulating levels of cyclosporine A >3,000 ng/mL in all experimental animals treated with cyclosporine A, whereas cyclosporine A levels were not detectable in vehicle-treated control animals (results not shown). Cyclosporine A treatment did not have a significant effect on the life span of any of the control animals, but completely abolished the increased survival provided by TK combined with Flt3L. At 40 days post tumor implantation and 30 days post gene therapy, survival of animals treated with both TK and Flt3L and cyclosporine A was reduced to the level of survival of animals treated with TK alone (Fig. 3D). Thus, the beneficial therapeutic effects of TK + Flt3L in the large glioma model was completely abolished by immunosuppression by cyclosporine A (Fig. 3D).

Brain Neuropathology of Long-term Survivors after Gene Therapy with RAdTK + RAdFlt3L

Rats that survived long-term after RAdTK + RAdFlt3L treatment were subjected to detailed neuropathologic analysis to assess the potential existence of inflammatory and neuropathologic side effects. All animals displayed enlarged ipsilateral ventricles indicative of striatal tissue loss as well as scar tissue at the site of tumor implantation and RAd injection (Fig. 4A, full brain image). High levels of ED1, MHC I, and MHC II staining were observed in the ipsilateral hemisphere near the injection site (Fig. 4A). CNS-1 cells...
express high levels of the intermediate filament vimentin. Whereas vimentin staining consistent with tumor cells was not detected (Fig. 4A), vimentin staining was up-regulated on the ipsilateral hemisphere consistent with reactive gliosis. Low but above background levels of CD8, CD45R, and CD161a-expressing cells were also detected near the site of tumor location and virus injection (Fig. 4B).

Depletion of Macrophages or CD4+ Cells but not CD8+ or Natural Killer CellsEliminates Therapeutic Efficacy of RAdTK + RAdFlt3L Treatment

To evaluate the extent and specificity of the depleting antibody treatments, naïve, non–tumor-bearing animals were injected once with 1 mg OX-8, OX-34, or normal mouse IgG; 0.5 mg NK3.2.3 or 2 mL clodronate or PBS-filled liposomes. Seven days later, spleens were harvested and evaluated for cell depletion. Each treatment responded as expected, specifically eliminating its target immune cell type (Fig. 5B) either NK (3.2 × 10^6 ± 1.2 × 10^6 control, 9.3 × 10^5 ± 2.7 × 10^6 NK 3.2.3 depleted), macrophages (7.8 × 10^6 ± 2.3 × 10^6 control, 2.87 × 10^6 ± 1.4 × 10^6 clodronate depleted), CD8 (1.6 × 10^6 ± 6 × 10^5 control, 4.1 × 10^5 ± 3.3 × 10^7 OX-8 depleted), or CD4 (6.9 × 10^5 ± 2.4 × 10^6 control, 4.5 × 10^7 ± 4.5 × 10^5 OX-34 depleted).

To deplete cells in large tumor-bearing animals, the latter were injected: OX-8 (to deplete CD8+ cells), OX-34 (to deplete CD4+ cells), NK 3.2.3 (to deplete NK cells), or clodronate (clodronate-filled liposomes; to deplete macrophages). Control animals were injected with normal mouse immunoglobulin or PBS-filled liposomes.

To deplete cells in large tumor-bearing animals, the latter were injected: OX-8 (to deplete CD8+ cells), OX-34 (to deplete CD4+ cells), NK 3.2.3 (to deplete NK cells), or clodronate (clodronate-filled liposomes; to deplete macrophages). Control animals were injected with normal mouse immunoglobulin or PBS-filled liposomes. Twenty-four hours after depletion, animals were intratumorally injected with either saline or RAdTK + RAdFlt3L. Whereas animals treated only with saline succumbed to brain tumors 13 to 19 days following CNS-1 cell implantation, 70% of RAdTK + RAdFlt3L + normal mouse immunoglobulin or PBS-filled liposomes–treated animals survived 35 days after implantation of CNS-1 cells (Fig. 5). Animals treated with RAdTK + RAdFlt3L and depleted of macrophages succumbed to brain tumors as rapidly as saline-treated animals. CD4+ cell–depleted animals survived longer than macrophage-depleted or saline-treated animals but did not survive long-term. Most CD8+ and NK cell–depleted animals survived as well as control mouse immunoglobulin or PBS liposome–treated animals. Comparison of all survival curves by log rank analysis (GraphPad...

Figure 3. Combined treatment with RAdTK and RAdFlt3L significantly enhances survival in a large brain tumor model and cyclosporine A eliminates the efficiency of combined treatment. A, rats with large tumors were treated 10 days after CNS-1 cell implantation with either saline (○), or 1 × 10^6 i.u. RAd0 (○), RAdTK (△), RAdFlt3L (▼), or RAdTK/Flt3L (▲). Whereas neither saline, RAd0, or RAdFlt3L altered survival with all animals dying ~ 25 days after tumor implantation, RAd TK prolonged survival in 20% of animals. RAdTK + Flt3L prolonged survival in 70% of animals. B, rats with large tumors were treated 10 days after CNS-1 cell implantation with either saline (○) or 1 × 10^6 i.u. RAd0 (○), RAdTK (△), RAdCD40L (▲), or RAd TK/RA cD40L (●). Treatment with RAdTK resulted in 20% survival, whereas combined treatment with RAdCD40L resulted in 40% survival. C, rats with large tumors were treated 10 days after CNS-1 cell implantation with either saline (○) or 1 × 10^6 i.u. RAd0 (○), RAdTK (△), RAdIL-12 (●), or RAd TK + RAdIL-12 (▲). Treatment with either RAdTK or RAdTK + RAdIL-12 resulted in 20% survival. Statistical analysis for (A) to (C) was done as indicated in Materials and Methods. Survival of animals treated with RAdTK + RAdFlt3L was statistically significantly increased compared with animals treated with either RAdTK or RAdTK + RAdIL-12 (**, P < 0.005); although the survival of animals treated with RAdTK + RAdCD40L seemed increased compared with animals treated with either RAdTK or RAdTK + RAdIL-12, this difference was not statistically significant. No statistically significant differences were found between RAdTK and RAdTK/RadIL-12, or between RAd0, RAdFlt3L, RAdIL-12, or RAdCD40L treatments. D, survival of animals treated with the immunosuppressant cyclosporine A (solid lines are without cyclosporine A and dashed lines are with cyclosporine A in each treatment condition). Animals were immunosuppressed with cyclosporine A beginning day 7 after tumor implantation and continuing daily throughout the experiment. Animals treated with RAdTK + Flt3L displayed increased survival only when not treated with cyclosporine A. Treatment of animals injected in the brain with RAdTK + Flt3L with cyclosporine A reduced the efficiency of the combined treatment to that of RAdTK alone. Treatment of animals with RAdTK and cyclosporine A reduced the efficiency of RAdTK further, potentially suggesting that the effectiveness of RAdTK is due to immunostimulation. Animals treated with RAdhsFlt3L, with or without cyclosporine A, had no effect on animal survival. Statistical analysis was done as described in Materials and Methods. Animals treated with RAdTK + Flt3L – cyclosporine A showed statistically significant increased survival compared with those injected with RAdTK + RAdFlt3L + cyclosporine A, or those treated only with RAdTK, indicated by arrows (**, P < 0.005). None of the other survival curves were statistically significantly different.

www.aacrjournals.org 7199 Cancer Res 2005; 65: (16). August 15, 2005
Prism software) indicates a statistically significant difference for both macrophage and CD4+-depleted animals \((P < 0.0001)\).

**Brain and Spinal Cord Autoimmunity Were Not Found in Animals Treated with RAdFlt3L + RAdTK**

A possible concern with an immunologic therapy against brain tumors is that the delivery of powerful proinflammatory/immunostimulatory genes might induce systemic anti–central nervous system (CNS) immune responses. Experimental allergic encephalomyelitis (EAE), for example, primarily targets the spinal cord. To determine the presence of such putative adverse side effects, spinal cords of RAdTK + RAdFlt3L–treated animals that had survived for up to 6 months (Fig. 6) were analyzed to determine the presence and distribution of inflammatory infiltrates (T cells and macrophages) in the meninges and within the spinal cords. Inflammatory infiltrates of T cells across all groups were very low (10-30 cells/section), but higher than normal control animals (0-2 T cells per section). In one animal (injected with TK + IL12), we found a few typical perivascular inflammatory infiltrates, similar in quantity to those found in very mild subclinical EAE (this animal had the largest forebrain tumor present; data not shown). No animal displayed overt symptoms of EAE. The distribution of macrophages throughout the spinal cord, and especially throughout the corticospinal tract, indicates a lesion in the pyramidal tract, most likely a lesion to the axon tracts of the internal capsule due to the tumor growth or even a small lesion to the axon fibers of the internal capsule. Even a direct or indirect (compression) lesion to the capsula interna, where the pyramidal tract is located in the forebrain, will produce visible lesions within the corticospinal tract in the spinal cord. This spinal cord inflammation is compatible

---

**Figure 4.** Inflammatory responses observed in the CNS of rats in which RAdTK + RAdFlt3L resulted in tumor regression. Male Lewis rats bearing large tumors were injected with RAdTK+RAdFlt3L. Animals still surviving at 2 months were sacrificed and brain sections were stained. A, whereas no residual tumor was observed, animals show enlarged ventricles (indicated by arrows in MHC I staining of full brain) and immune marker up-regulation. Ipsilateral and contralateral sections of striatum are shown. Evidence of immune cell infiltration at and around the injection site is observed in increased levels of ED1-, MHC I–, MHC II–, and vimentin-positive cells. B, CD161a-, CD45R-, and CD8-positive cells were observed near the injection site at low levels. Low-magnification images were taken at ×1; bar, 1,000 µm. Higher-magnification images were taken at ×40 near the injection site as indicated by a black box in the low-magnification field; bars, 50 µm.
with ongoing axon tract degeneration, but no evidence of autoimmune spinal cord inflammation and/or oligodendrocyte attack was detected.

Discussion

Recombinant adenovirus vectors have shown promise in preclinical, and most recently in randomized, controlled clinical studies (9–11, 24, 39, 40). Complete tumor elimination has not been as forthcoming in clinical studies (9, 10, 24, 39, 40). This highlights shortcomings in the brain tumor models currently used to evaluate the clinical efficacy of adenoviral therapies. To address this issue, we have developed a large syngeneic brain tumor model in immunocompetent rats. This model more faithfully predicts the outcome of gene therapies observed in a clinical setting.

Vaccine immunotherapy for cancer has recently shown great promise with the discovery that dendritic cells play a pivotal role in antigen presentation. The use of dendritic cell–based vaccines is currently ongoing in about 20 phase II and at least 1 phase III clinical trial in the United States, many of which are showing promising results (57, 58). Because RAdFlt3L, dendritic cell activation (RAdCD40L), or a powerful cytokine that activates TH1 responses (RAdIL-12), Interleukin-12 is a powerful stimulator of cell-mediated antitumor immune responses and has shown promising results in various clinical trials (57, 58). Because RAdTK would be cytotoxic to tumor cells, we hypothesized that tumor killing would provide antigenic tumor epitopes to dendritic cells in situ when coadministered with RAdFlt3L or RAdCD40L. Eventually, this could stimulate an antitumor immune response, tumor reduction or elimination, and increased survival. Coadministration of RAdFlt3L + RAdTK was found to greatly increase the survival of rats in our large brain tumor model (≥70%, P ≤ 0.005). Also, increased survival was noted when we used RAdCD40L in combination with RAdTK, but this did not achieve statistical significance. RAdIL-12 did not increase survival in animals bearing large tumors when codelivered with RAdTK. Cyclosporine A completely negated the improved survival with RAdFlt3L + RAdTK; this supports the putative role played by the immune system in this antitumor response.

www.aacrjournals.org 7201 Cancer Res 2005; 65: (16). August 15, 2005

Figure 5. Depletion of specific subsets of immune cell alters therapeutic efficacy of RAdTK + Flt3L in macrophage and CD4+ cell–depleted animals. A, all animals were injected with 5,000 CNS-1 glioma cells. Nine days later, specific subsets of immune cells were depleted by i.p. injection of 1 mg OX-8, OX-34 or normal mouse serum, 0.5 mg of NK3.2.3, or 2 mL clodronate or PBS-filled liposomes (n = 6). Twenty-four hours following immune cell depletion, saline or RAdTK + Flt3L was intratumorally injected. A, Kaplan-Meier survival curve of all depleted animals (serum and PBS liposome, □; OX-8, △; OX-34, ○; NK3.2.3, ▲; and clodronate, △) and control groups (saline treated, ●). B, depletion efficiency and specificity was evaluated by flow cytometry in splenocytes from immune cell depleted or control animals seven days after depletion (n = 4). All samples were gated on lymphocyte populations by FSC and SSC. NK cells were identified as CD3, CD161a+. Macrophages were identified after gating CD45+ lymphocytes as CD4+, CD11b intermediate populations. CD4 cells were identified as CD4+, CD8+ cells were identified as CD4+, CD8+ after gating respective populations for CD3+ lymphocytes. Numbers represent total number of a given cell population per spleen ± SE (n = 4).
We observed elevated reactive gliosis, macrophage/microglial, MHC I, and MHC II staining around the site of injection in long-term survivors injected RAdTK + RAdFlt3L. In addition, CD8, CD45R, and CD161a expression was also observed in these animals, demonstrating that the combination therapy used was capable of inducing significant inflammatory responses at the site of injection. The inhibitory effect of cyclosporine A strongly suggests the presence of an immunocomponent mediating the effect of the combined gene therapies on tumor regression. However, due to the complex mechanism of action of this powerful immunosuppressant, individual lymphocyte subtypes mediating glioma elimination cannot be identified. To advance toward the mechanism of action of our combined gene therapy approach, we treated tumors with the combined gene therapies in the presence of depleting antibodies or clodronate-filled liposomes that would selectively eliminate individual populations of lymphocytes and macrophages. These experiments show that presence of CD4+ T cells and macrophages are necessary for the combined gene therapy with Flt3L and TK to be effective, but that CD8+ T cells and NK cells are dispensable for glioma eradication.

A number of cells in the brain can express MHC II, and thus could present tumor antigens to CD4+ T cells. Activated macrophages and microglia, as well as endothelial cells in the brain, express MHC II, and we have tested that the CNS-1 cells are also able to express MHC II, although at much lower levels than MHC I. Thus, a number of cells within the brain could present tumor antigens to the CD4+ T cells, which upon entry into the brain environment could release IFNγ, as well as other cytokines to stimulate the activity, and especially the phagocytic capacity of recruited macrophages. The killing of tumor cells with TK and ganciclovir would increase local inflammation and allow tumor cells to express signals to the macrophages, eventually leading to their demise. Although CD4+ T cells could be thought of having other roles, e.g., as regulatory T cells, the fact that CD8+ T cells are not necessary for tumor rejection makes this unlikely. Also, in our model, CD4+ T cells could themselves be cytotoxic to the tumors, either through the release of IFNγ or tumor necrosis factor α, or through interactions between FasL and Fas. Although the role of CD4+ T cells in tumor elimination has not be clearly elucidated, similar CD4+ T cell–centered tumor elimination mechanisms have been recently reported in models of myeloma (59), lymphoma (60), and cervical cancer (61).

A concern of all vaccine immunotherapies is the development of autoimmune diseases in response to the vaccine. Although adverse autoimmune reactions have not yet been observed in clinical studies, the use of adenovirus to stimulate an immune response against tumor-specific antigens differs from these therapies. Lewis rats are susceptible to the induction of EAE and thus provide a powerful model to assess long-term inflammatory or autoimmune side effects. Although we observed elevated T-lymphocyte infiltration in the meninges and within the spinal cord of animals treated with RAdFlt3L compared with control animals, the levels of infiltration were very low and no animal displayed clinical symptoms of EAE.

In conclusion, we have developed a large preclinical model for glioma that reflects more accurately the clinical situation when administering recombinant adenoviral therapies. We have shown that RAdFlt3L strongly promotes survival in rats bearing large brain tumors when coadministered with RAdTK. Further, this therapy does not elicit an appreciable autoimmune or autoimmune response in animals. Our data suggests that RAdFlt3L + RAdTK may be a useful adjuvant for increasing the numbers of dendritic cells and enhancing long-term survival and tumor regression in glioblastoma and warrants further development for its implementation in clinical trials.

![Figure 6](Image 132x149 to 456x344)

**Figure 6.** Spinal cord neuropathology of animals surviving a large brain tumor for 6 months. Representative animals are illustrated herein. A and C, animals treated with RAdTK + RAdFlt3L and that survived tumor treatment for 6 months; A, distribution of macrophages (stained with ED1) in the corticospinal tract (outlined by black arrows), compatible with forebrain lesions to the pyramidal tract as caused by the growing tumor, and (C) indicates the distribution of T cells in the meninges of the same group of animals. Although the values of T cells in the meninges of these animals is extremely low, it is nevertheless higher than in animals not receiving any treatment. B, spinal cord of an animal treated with RAdTK and RAdCD40L stained with the Kluwer histochemical stain for myelin. Notice the unilateral area of demyelination in the spinal cord (outlined by black arrows), compatible with a lesion to the descending spinocortical tract, most possibly due to forebrain lesions to the pyramidal tract. D, largest infiltration of the meninges with T cells of any of the examined animals, and that was seen in an animal treated with RAdFlt3L and RAdIL12 (this animal displayed the largest tumor growth and brain inflammation at the time of sacrifice; data not shown). Bar, for all panels, shown in (D), 80 μm.
References

Combined Immunostimulation and Conditional Cytotoxic Gene Therapy Provide Long-term Survival in a Large Glioma Model

Sumia Ali, Gwendalyn D. King, James F. Curtin, et al.


Updated version Access the most recent version of this article at: http://cancerres.aacrjournals.org/content/65/16/7194

Cited articles This article cites 60 articles, 17 of which you can access for free at: http://cancerres.aacrjournals.org/content/65/16/7194.full.html#ref-list-1

Citing articles This article has been cited by 16 HighWire-hosted articles. Access the articles at: /content/65/16/7194.full.html#related-urls

E-mail alerts Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.